Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.34 |
| ▸ | FSHR | P23945 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1439601 | 0.98 | TSHR (0.39) | TSHRALDH1A1RAB9AFFAR3FSHR | |
| SCHEMBL14961961 | 0.94 | TSHR (0.44) | TSHRALDH1A1RAB9AFFAR3FSHR | |
| SCHEMBL11167364 | 0.85 | APOBEC3A (0.35) | TSHRALDH1A1FFAR3FSHRSMN1; SMN2 | |
| SCHEMBL8080075 | 0.83 | ALDH1A1 (0.32) | TSHRALDH1A1FFAR3TDP1MEN1 | |
| SCHEMBL24763400 | 0.82 | OPRM1 (0.37) | TSHRALDH1A1RAB9ATDP1MEN1 | |
| SCHEMBL3020102 | 0.82 | TSHR (0.40) | TSHRALDH1A1RAB9AFFAR3TDP1 | |
| SCHEMBL13518446 | 0.82 | TSHR (0.41) | TSHRALDH1A1RAB9AFSHRTDP1 | |
| SCHEMBL232259 | 0.80 | TSHR (0.39) | TSHRALDH1A1RAB9AFSHRTDP1 | |
| SCHEMBL16949830 | 0.80 | TSHR (0.39) | TSHRALDH1A1RAB9AFSHRTDP1 | |
| SCHEMBL11155103 | 0.78 | KDM4E (0.39) | ALDH1A1FFAR3MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | claimed |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-18 | — | — | US | disclosed |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-18 | — | — | US | disclosed |
| US-11518745-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-12-06 | — | — | US | disclosed |
| US-20200407320-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-12-31 | — | — | US | disclosed |
| US-10822306-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-11-03 | — | — | US | disclosed |
| US-10428058-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-10-01 | — | — | US | disclosed |
| US-20190284181-A9 | PRODRUGS OF NH-ACIDIC COMPOUNDS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-09-19 | — | — | US | disclosed |
| US-20190276406-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-09-12 | — | — | US | disclosed |
| US-10351529-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-07-16 | — | — | US | disclosed |
| EP-0587311-A1 | Peptides capable of inhibiting the activity of HIV protease, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1994-03-16 | — | — | EP | disclosed |
| EP-0570245-A2 | Octahydronaphthalene oxime derivatives for cholesterol biosynthesis inhibition, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1993-11-18 | — | — | EP | disclosed |
| EP-0560613-A1 | Antimicrobial carbapenem derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1993-09-15 | — | — | EP | disclosed |
| US-5242914-A | 2-(heterocyclylthio) carbapenem derivatives, their preparation and their use as antibiotics | SANKYO COMPANY, LIMITED (JP) | 1993-09-07 | — | — | US | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
| EP-0518558-A1 | 1-Methylcarbapenem derivatives, their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1992-12-16 | — | — | EP | disclosed |
| US-5104867-A | 2-(HETEROCYCLYLTHIO)CARBAPENEM DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ANTIBIOTICS | SANKYO COMPANY, LIMITED (JP) | 1992-04-14 | — | — | US | disclosed |
| EP-0443883-A1 | Carbapenem derivatives having antibiotic activity, their preparation and their use | Sankyo Company Limited (JP) | 1991-08-28 | — | — | EP | disclosed |
| EP-0437016-A2 | Lipid A analogues having immunoactivating and anti-tumour activity | Sankyo Company Limited (JP) | 1991-07-17 | — | — | EP | disclosed |
| EP-0337637-A1 | 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407320-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | TSHR 1280/4885ALDH1A1 599/4885RAB9A 853/4885 |
| US-10351529-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | TSHR 1280/4885ALDH1A1 599/4885RAB9A 853/4885 |
| US-20190284181-A9 | PRODRUGS OF NH-ACIDIC COMPOUNDS | SI, NAAA, NIT2 | TSHR 3738/4885ALDH1A1 1082/4885RAB9A 1430/4885 |
| US-10428058-B2 | Prodrugs of NH-acidic compounds | SI, NAAA, NIT2 | TSHR 3738/4885ALDH1A1 1082/4885RAB9A 1430/4885 |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | TSHR 1280/4885ALDH1A1 599/4885RAB9A 853/4885 |
| US-11518745-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | TSHR 1280/4885ALDH1A1 599/4885RAB9A 853/4885 |
| US-20190276406-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | TSHR 1280/4885ALDH1A1 599/4885RAB9A 853/4885 |
| US-10822306-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | TSHR 1280/4885ALDH1A1 599/4885RAB9A 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.